PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed

A change in projected discounts resulted from ICER’s decision to broaden its consideration of the benefit of PCSK9 treatment to span a patient’s lifetime, including outcomes in patients over 75.

The Institute for Clinical and Economic Effectiveness’ draft cost-effectiveness report on the PCSK9 inhibitors has been updated in response to stakeholder comments and now suggests somewhat less of a price discount than originally thought necessary to allow the drugs to be considered cost-effective.

In its original draft report, released Sept. 8, ICER suggested discounts of at least 67% would be needed for Amgen Inc.’s Repatha and Sanofi and Regeneron Pharmaceuticals...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America